Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide

Safinamide (SAF) is a new drug developed for the treatment of Parkinson’s disease (PD). It is a benzylamino derivative with multiple mechanisms of action and antiparkinsonian, anticonvulsant, and neuroprotective properties. SAF inhibits monoamine oxidase B and dopamine reuptake and glutamate release...

Descripción completa

Detalles Bibliográficos
Autores principales: Stocchi, Fabrizio, Torti, Margherita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751980/
https://www.ncbi.nlm.nih.gov/pubmed/26917951
http://dx.doi.org/10.2147/DDDT.S77749

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751980/
https://www.ncbi.nlm.nih.gov/pubmed/26917951
http://dx.doi.org/10.2147/DDDT.S77749

Ejemplares similares